Bimat: Advanced Ophthalmic Solution for Glaucoma Control
| Product dosage: 0.3mg | |||
|---|---|---|---|
| Package (num) | Per bottle | Price | Buy |
| 1 | $51.60 | $51.60 (0%) | 🛒 Add to cart |
| 2 | $43.00 | $103.20 $86.00 (17%) | 🛒 Add to cart |
| 3 | $37.27 | $154.80 $111.80 (28%) | 🛒 Add to cart |
| 4 | $36.55 | $206.40 $146.20 (29%) | 🛒 Add to cart |
| 5 | $34.40 | $258.00 $172.00 (33%) | 🛒 Add to cart |
| 6 | $32.97 | $309.60 $197.80 (36%) | 🛒 Add to cart |
| 7 | $31.94 | $361.20 $223.60 (38%) | 🛒 Add to cart |
| 8 | $31.18 | $412.80 $249.40 (40%) | 🛒 Add to cart |
| 9 | $29.62 | $464.40 $266.60 (43%) | 🛒 Add to cart |
| 10 | $28.38
Best per bottle | $516.00 $283.80 (45%) | 🛒 Add to cart |
Synonyms | |||
Bimat is a prescription ophthalmic solution containing the active ingredient bimatoprost, a prostaglandin analog specifically formulated to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. By enhancing the outflow of aqueous humor through both the trabecular meshwork and uveoscleral pathways, Bimat provides a sustained, once-daily mechanism for IOP reduction. It represents a first-line therapeutic option endorsed by ophthalmological guidelines worldwide, offering a favorable balance of efficacy, tolerability, and dosing convenience for long-term management of chronic ocular conditions.
Features
- Contains bimatoprost 0.01% or 0.03% as the active pharmaceutical ingredient
- Preservative-free and benzalkonium chloride-free formulations available
- Sterile, isotonic ophthalmic solution with pH optimized for ocular comfort
- Supplied in 2.5 mL or 5 mL tamper-evident dropper bottles
- Once-daily dosing regimen for consistent 24-hour IOP control
Benefits
- Significantly reduces intraocular pressure, lowering risk of glaucomatous optic nerve damage
- Provides consistent 24-hour IOP reduction with single daily administration
- Demonstrates excellent long-term efficacy with minimal tachyphylaxis
- May enhance periocular eyelash growth as a secondary beneficial effect
- Offers improved ocular surface compatibility with preservative-free options
- Reduces treatment burden through simple once-daily dosing schedule
Common use
Bimat is primarily indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It is frequently prescribed as monotherapy but may be used concomitantly with other IOP-lowering medications when additional pressure reduction is required. The medication is suitable for long-term management of chronic glaucoma and may be used in patients who have demonstrated inadequate response to other ocular hypotensive agents. Clinical studies have established its efficacy across diverse patient populations, including those with pigmentary glaucoma and pseudoexfoliative glaucoma.
Dosage and direction
The recommended dosage is one drop in the affected eye(s) once daily in the evening. Administration frequency should not exceed once daily as more frequent administration may diminish the IOP-lowering effect. Patients should be instructed to gently shake the bottle before use. Contact lenses should be removed prior to instillation and may be reinserted 15 minutes following administration. Proper technique includes tilting the head backward, pulling down the lower eyelid to create a pouch, instilling one drop, and closing the eye gently for 1-2 minutes while applying light pressure to the nasolacrimal duct to minimize systemic absorption.
Precautions
Patients should be advised that Bimat may gradually increase brown pigmentation of the iris, which may be permanent. Eyelid skin darkening may occur and may be reversible upon discontinuation. The solution may gradually change eyelashes and vellus hair in the treated eye, including increased length, thickness, and number of lashes. Patients should be monitored for macular edema, particularly in aphakic patients, pseudophakic patients with torn posterior lens capsule, or patients with known risk factors for macular edema. Use with caution in patients with active intraocular inflammation, history of herpes simplex keratitis, or significant renal or hepatic impairment.
Contraindications
Bimat is contraindicated in patients with known hypersensitivity to bimatoprost or any component of the formulation. It should not be used in patients with active ocular infections, particularly viral infections of the cornea and conjunctiva. The medication is contraindicated in patients with angle-closure glaucoma unless accompanied by iridotomy. Use is not recommended during pregnancy unless the potential benefit justifies the potential risk to the fetus. Breastfeeding mothers should exercise caution and consider discontinuing nursing or the medication.
Possible side effects
The most frequently reported ocular adverse reactions (approximately 15-45% of patients) include conjunctival hyperemia, growth of eyelashes, and ocular pruritus. Between 3-10% of patients may experience ocular dryness, visual disturbance, foreign body sensation, eye pain, pigmentation of the periocular skin, blepharitis, cataract, superficial punctate keratitis, eyelid erythema, ocular irritation, and eyelash darkening. Less common side effects (<3%) include iritis, cystoid macular edema, headaches, asthenopia, conjunctival edema, dizziness, and ocular inflammation. Systemic effects are rare but may include upper respiratory tract infections and mild to moderate chest pain.
Drug interaction
Although ocular administration minimizes systemic exposure, potential interactions may occur with other prostaglandin analogs, which may reduce the hypotensive effect. Concomitant use with pilocarpine may decrease the efficacy of bimatoprost. No clinically significant interactions have been observed with beta-blockers, carbonic anhydrase inhibitors, or alpha-agonists when used in combination therapy. Patients using medications that affect blood clotting should be monitored due to potential increased vascular permeability. The preservative benzalkonium chloride may be absorbed by soft contact lenses.
Missed dose
If a dose is missed, patients should instill the drop as soon as they remember, unless it is nearly time for the next scheduled dose. In such cases, the missed dose should be skipped, and the regular dosing schedule resumed. Patients should not instill two drops to make up for a missed dose. Consistency in dosing is important for maintaining stable intraocular pressure control, but occasional missed doses are unlikely to significantly affect long-term IOP management. Patients should maintain their regular appointment schedule with their ophthalmologist regardless of missed doses.
Overdose
Ocular overdose is unlikely to produce serious effects beyond ocular irritation, conjunctival hyperemia, or transient blurred vision. If more than one drop is accidentally instilled, no specific treatment is necessary. Systemic overdose through ocular administration is improbable due to minimal systemic absorption. However, if the contents of the bottle are ingested orally, symptomatic treatment should be instituted with gastric lavage if indicated. Supportive measures should be employed based on clinical manifestations. Medical attention should be sought if accidental ingestion occurs, particularly in children.
Storage
Store at controlled room temperature 15°-25°C (59°-77°F). Protect from light and excessive heat. Keep the bottle tightly closed when not in use. Once opened, the solution should be used within 28 days. Do not freeze. Keep out of reach of children and pets. Do not use if the solution changes color or becomes cloudy. The dropper tip should not touch any surface, including the eye, to avoid contamination. Discard any unused solution after the expiration date printed on the packaging.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Bimat is a prescription medication that should be used only under the supervision of a qualified healthcare professional. Individual response to treatment may vary. Patients should not alter their dosage or discontinue treatment without consulting their ophthalmologist. The complete prescribing information should be consulted before initiating therapy. Only licensed healthcare providers can determine the appropriate treatment based on individual patient circumstances.
Reviews
Clinical studies demonstrate that approximately 70-80% of patients achieve target IOP reduction with Bimat monotherapy. In comparative trials, Bimat showed non-inferiority to latanoprost with potentially better tolerability in some patient subsets. Long-term extension studies indicate maintained efficacy over 24 months of continuous use with stable safety profile. Patient satisfaction surveys report high compliance rates due to once-daily dosing and acceptable ocular comfort. Ophthalmologists frequently note the additional benefit of enhanced eyelash growth as a positive secondary effect that improves patient adherence to therapy.